BELR unit plans $499 breath biomarker device for consumer pre-orders

By AI, Created 7:28 PM UTC, May 18, 2026, /AGP/ – Bell Rose Capital’s 4BiddenKnowledge unit plans to bring its 4BK BioKey breath biomarker wellness device to the consumer pre-order market, with fulfillment targeted about six months after purchase. The handheld platform is pitched as an educational, non-diagnostic tool for breath-based wellness insights and could mark a new consumer category in at-home health awareness.

Why it matters: - Bell Rose Capital’s wholly owned subsidiary 4BiddenKnowledge is trying to create a consumer market for breath-based wellness education. - The 4BK BioKey is positioned as a non-invasive handheld device that could give users metabolic and lifestyle awareness from a single breath. - The company is targeting a $499 pre-order price, which places the product in an early consumer hardware category rather than a clinical device market. - Consumers and investors can find more information at the company’s website.

What happened: - Bell Rose Capital said 4BiddenKnowledge plans to bring the patent-pending 4BK BioKey to the consumer pre-order market. - Initial fulfillment is targeted for about six months after order placement. - The device is branded as “The Breath of Knowledge.” - The announcement was dated May 19, 2026, from Boca Raton, Florida.

The details: - BioKey is being developed as a handheld consumer breathomics platform focused on breath-based biomarker education. - The platform is designed to analyze 60-plus breath biomarkers and biomarker signatures. - Planned sensing methods include metal oxide semiconductor sensors, non-dispersive infrared CO₂ sensing, and electrochemical sensing platforms. - The company says human breath contains more than 1,000 volatile organic compounds, or VOCs, that may reflect metabolic and physiological processes. - Planned coverage areas include metabolic wellness, oxidative stress, respiratory wellness, gastrointestinal wellness, hepatic wellness, cardiovascular wellness, neurological wellness, environmental exposure, and emerging research categories. - The current roadmap includes a disposable mouthpiece, guided breath testing, CO₂-based sample validation, onboard display functionality, Bluetooth connectivity, and AI-assisted wellness insights. - The device is being designed to show certain results on the built-in display without requiring a smartphone. - The BioKey app ecosystem is being designed for guided testing, trend visualization, lifestyle correlation, AI recommendations, PDF export, and integration with Apple HealthKit and Google Fit. - The ecosystem also includes educational content through the 4BiddenKnowledge Academy. - The deck describes a tiered subscription model with free, premium, pro, and enterprise or clinic options. - Bell Rose Capital said the device is not intended to diagnose, treat, cure, mitigate, or prevent any disease or medical condition. - The device is also not intended to replace physician guidance, clinical testing, laboratory diagnostics, or any authorized medical device. - The company expects the consumer pre-order price to be $499.00.

Between the lines: - The announcement frames BioKey as a wellness and education product, not a medical device, which may help the company avoid direct claims tied to diagnosis or treatment. - The focus on app integration, AI feedback, and subscription tiers suggests the device is being built as part of a broader digital wellness ecosystem, not a one-time hardware sale. - The company’s language points to a bet that consumers will pay for personalized health awareness tools even when those tools stop short of clinical use. - Billy Carson, inventor of BioKey and CEO of Bell Rose Capital, said the goal is to help people understand their bodies through breath as a non-invasive window into wellness and optimization.

What’s next: - Bell Rose Capital said additional details on pre-orders, product availability, app features, subscription options, and the commercial launch schedule will be released as development milestones are completed. - The company is targeting fulfillment about six months after orders are placed. - The broader rollout will likely depend on product development progress, manufacturing readiness, and market response.

The bottom line: - Bell Rose Capital is moving to commercialize a breath-analysis device aimed at wellness education, with a $499 consumer launch plan and a six-month fulfillment target.